Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer

Equality Impact Assessment (Guidance development) (PDF 143 KB)

Register of interests (PDF 126 KB)

Final draft guidance

Final appraisal document (PDF 243 KB)

Committee papers (PDF 12.14 MB)

Public committee slides (PDF 946 KB)

Final scope (PDF 182 KB)

Final stakeholder list (PDF 211 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 299 KB)

Equality impact assessment (Scoping) (PDF 126 KB)

Draft scope post referral (PDF 222 KB)

Draft matrix post referral (PDF 210 KB)